On May 27, 2020 Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, reported that Randall Schatzmann, Ph.D., chief executive officer of Bolt, will present a company overview at the 2020 Jefferies Virtual Healthcare Conference on Wednesday, June, 3, 2020 at 2:00 PM ET (Press release, Bolt Biotherapeutics, MAY 27, 2020, View Source [SID1234558533]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!